TPG's AskBio stake more than doubles amid sale to Bayer

Bayer agreed to pay $2bn upfront for the TPG-backed gene therapy company, plus a potential for another $2bn in milestone payments.

27 October 2020•3 mins read
cell and gene therapy, gene therapy
LinkedInXEmail
LinkedInXEmail

Related articles